

News

06 July 2006

Curidium announces new Director of Psychiatry Research

London , UK , 06 July 2006

Curidium Ltd, a drug discovery and development company focused on identifying targeted medicines to treat patients more effectively, announced the appointment of Dr Smita Price as its new Director of Psychiatry Research.

Dr Price (formerly Patel) joins from Merck Neuroscience Research Centre, UK, where she was leader of the Target Evaluation team within Exploratory Psychiatry. Dr Price brings over 15 years experience in Central Nervous System (CNS) drug discovery and development. At Merck, she successfully managed multiple CNS projects and contributed to the advancement of in-licensing opportunities, CNS portfolio management and drug development strategies. Prior to joining Merck, Dr Price conducted research on epilepsy as a Postdoctoral Fellow with Professor Brian Meldrum at the Institute of Psychiatry in London. She holds a PhD in Physiology from the University of Manchester and a BSc (Hons) in Pharmacology from the University of Cardiff.

"I am delighted to be joining Curidium at such an exciting time in the Company's development," said Dr Price. "I have been impressed with the Curidium team and the proprietary technology they have developed."

Dr Anne T. Bruinvels, CEO of Curidium said, "Dr Price has considerable knowledge in psychiatry research which will be significant as we seek to become a leading player in drug discovery and development of targeted medicines for Central Nervous System diseases. We are delighted to welcome Smita to the team."

For more information about Curidium, please contact:

Dr. Anne T. Bruinvels, CEO

Curidium Medica plc.
Hamilton House
Mabledon Place
London,,WC1H 9BB
United Kingdom
Phone:
Fax:
E-mail:

+44 (0)20 7554 8790
+44 (0)20 7554 8791
info@curidium.com

About Curidium

Curidium is a drug discovery and development company focused on identifying targeted medicines to treat patients more effectively.

Curidium has developed a novel and proprietary technology, Homomatrix®, to untangle the underlying mechanisms of human diseases. Curidium's technology identifies different patient subpopulations each having a distinct disease mechanism. This enables the generation of new diagnostic tools and medicines designed for a subgroup of patients and potentially offering improved safety and effectiveness.

Curidium is initially applying its core technology to diseases of the Central Nervous System. Curidium's intellectual property portfolio, combining novel diagnostic tests with new drug treatments in the area of Central Nervous System disorders, is believed to be one of the most advanced in the industry.

Curidium has developed a pipeline with four clinical candidates to treat psychiatric diseases, which were previously developed for other indications.

Curidium's approach to re-develop existing drugs as targeted medicines for the appropriate patient group is likely to reduce clinical trial cost, development timelines and regulatory risks

Curidium's business activities were started in 2001 by Dr Anne T. Bruinvels who has also developed the Company's proprietary research platform, Homomatrix®. Operating out of facilities based in central London (UK), Curidium has attracted a team experienced in the discovery, development and commercialisation of CNS focused drugs.

Further information on Curidium can be found at the Company's website: www.curidium.com

Curidium Medica plc © 2002-2005

Hamilton House, Mabledon Place, London WC1H 9BB, United Kingdom.

Email: info@curidium.com Tel.: +44 (0)20 7554 8790, Fax: +44 (0)20 7554 8791